Yim Juwon, Molloy Leah M, Newland Jason G
St. John Hospital and Medical Center, Detroit, MI, USA.
Children's Hospital of Michigan, Detroit, MI, USA.
Infect Dis Ther. 2017 Mar;6(1):57-67. doi: 10.1007/s40121-016-0144-8. Epub 2016 Dec 30.
Ceftaroline is a novel cephalosporin recently approved in children for treatment of acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia (CABP) caused by methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae and other susceptible bacteria. With a favorable tolerability profile and efficacy proven in pediatric patients and excellent in vitro activity against resistant Gram-positive and Gram-negative bacteria, ceftaroline may serve as a therapeutic option for polymicrobial infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and resistant Gram-positive infections that fail first-line antimicrobial agents. However, limited data are available on tolerability in neonates and infants younger than 2 months of age, and on pharmacokinetic characteristics in children with chronic medical conditions and those with invasive, complicated infections. In this review, the microbiological profile of ceftaroline, its mechanism of action, and pharmacokinetic profile will be presented. Additionally, clinical evidence for use in pediatric patients and proposed place in therapy is discussed.
头孢洛林是一种新型头孢菌素，最近被批准用于治疗儿童由耐甲氧西林金黄色葡萄球菌、肺炎链球菌和其他易感细菌引起的急性细菌性皮肤和软组织感染以及社区获得性细菌性肺炎（CABP）。头孢洛林具有良好的耐受性，在儿科患者中疗效得到证实，对耐药革兰氏阳性菌和革兰氏阴性菌具有出色的体外活性，可作为多重微生物感染、由对青霉素和头孢曲松耐药的肺炎链球菌引起的CABP以及一线抗菌药物治疗失败的耐药革兰氏阳性菌感染的治疗选择。然而，关于2个月以下新生儿和婴儿的耐受性以及患有慢性疾病的儿童和侵袭性、复杂性感染儿童的药代动力学特征的数据有限。在本综述中，将介绍头孢洛林的微生物学概况、作用机制和药代动力学概况。此外，还讨论了在儿科患者中使用的临床证据以及建议的治疗地位。
